All entries on Alfasigma across all areas, newest first. tag:eurotrack.ai,2026:en:en/companies/alfasigma 2026-08-11T06:00:00Z Eurotrack tag:eurotrack.ai,2026:fc7d4a03:en 2026-08-11T06:00:00Z

Italian pharmaceutical company Alfasigma signed a share purchase agreement with SEVER Life Sciences B.V. on 11 August 2026 for all shares in Netherlands-based Nordic Group B.V. (Nordic Pharma). Nordic Pharma has direct operations in 18 European countries as well as Canada and Japan, employs 265 people and generated around €190m in revenue in 2025; the main asset is its rheumatoid arthritis business around the methotrexate brand Nordimet, which complements Alfasigma's rheumatology portfolio (Jyseleca). Financial terms were not disclosed. — Source: https://www.biospace.com/press-releases/alfasigma-to-acquire-nordic-group-b-v-expanding-its-specialty-care-portfolio-and-presence-in-europe

tag:eurotrack.ai,2026:6b5d5751:en 2026-07-20T06:00:00Z

Italian pharma group Alfasigma announced on 20 July — during a visit by Lazio regional president Francesco Rocca to its Pomezia site (over 500 employees) — an investment plan of over €40 million for 2026/2027: new plant and technologies, insourcing of processes and a strengthening of production lines (reported via the Italpress agency). — Source: https://www.italpress.com/farmaceutica-da-alfasigma-un-nuovo-piano-di-investimenti-per-il-polo-di-pomezia/